Core Insights - The national medical insurance work conference held in Beijing on December 13, 2025, emphasized the strategic purchasing role of medical insurance in supporting the innovative development of the pharmaceutical industry [1] Group 1: Policy Initiatives - In 2026, the focus will be on promoting healthy competition and differentiated innovation within the pharmaceutical industry [1] - The implementation of measures to support the high-quality development of innovative drugs will be deepened, enhancing the multi-payment capabilities for innovative drugs [1] Group 2: Procurement Strategies - New rounds of national drug procurement and high-value medical consumables procurement will be conducted [1] - The ongoing promotion of national alliance procurement for traditional Chinese medicine and Chinese herbal pieces will continue [1] Group 3: Financial Efficiency - The goal is to achieve direct settlement for selected drugs and consumables from national procurement, with a focus on improving the efficiency of corporate receivables [1] - The Chinese drug price registration system will be leveraged to enhance multi-price discovery functions, aiding the international expansion of the Chinese pharmaceutical industry [1]